BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
SOURCE: Bridge Bio, Inc. QED Therapeutics, an affiliate company of BridgeBio, is an Emerald Sponsor of this year’s Achondroplasia & Skeletal Dysplasia Research Conference, June 28-30 in Baltimore, Maryland. This…